Trihexyphenidyl

Trade names

• PARGITAN

Actions

• Selective M1 muscarinic acetylcholine receptor antagonist.

Route of Administration

Oral

Bioavailability

Very limited pharmacokinetic data exist.

Plasma protein binding

Very limited pharmacokinetic data exist.

Half-life

3.3-4.1 hours

Metabolism

Unknown

Elimination

Very limited pharmacokinetic data exist.

Important side-effects

Memory problems, confusion, delirium, psychosis.

Dry mouth, constipation, ileus, urinary retention.

Tachycardia.

Should not be given to patients with untreated closed angle glaucoma.

Recommended dose

Start with 1 mg once daily.

Titrate after effect and tolerance by 2 mg increments at intervals of three to five days.

Maximum dose is 12-15 mg per day.

Renal impairment

Insufficient data exist on the safety of trihexyphenidyl in patients with impaired renal function.

Hepatic impairment

Insufficient data exist on the safety of trihexyphenidyl in patients with impaired hepatic function.